Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance

Journal of Clinical Investigation

Volumn 123, Issue 9, 2013, Pages 3848-3860

  Rabi, S Alireza ^a   Laird, Gregory M ^a   Durand, Christine M ^a   Laskey, Sarah ^a   Shan, Liang ^a   Bailey, Justin R ^a   Chioma, Stanley ^b   Moore, Richard D ^a   Siliciano, Robert F ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; PROTEINASE; VIRUS ENVELOPE PROTEIN;

ARTICLE; CONTROLLED STUDY; CYTOPLASM; DOSE RESPONSE; DRUG INHIBITION; GENE MUTATION; GENE SEQUENCE; LIFE CYCLE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; VIRION; VIRUS ENTRY;

CD4-POSITIVE T-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HEK293 CELLS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LOPINAVIR; MUTATION, MISSENSE; OLIGOPEPTIDES; PYRIDINES; SULFONAMIDES; VIRUS INTERNALIZATION;

EID: 84883537144     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI67399     Document Type: Article

References (69)

1. Thompson MA, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the international AIDS society-USA panel. JAMA. 2010;304(3):321-333.
2. Shen L, et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med. 2008;14(7):762-766. (Pubitemid 351951518)
3. Anderson J, Schiffer C, Lee SK, Swanstrom R. Viral protease inhibitors. Handb Exp Pharmacol. 2009;(189):85-110.
4. Jilek BL, et al. A quantitative basis for antiretroviral therapy for HIV-1 infection. Nat Med. 2012;18(3):446-451.
5. Perez-Valero I, Arribas JR. Protease inhibitor monotherapy. Curr Opin Infect Dis. 2011;24(1):7-11.
6. Shen L, et al. A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs. Sci Transl Med. 2011;3(91):91ra63.
7. .Swanstrom R, Wills JW. Synthesis, assembly, and processing of viral proteins. In: Coffin JM, Hughes SH, Varmus HE, eds. Retroviruses . Cold Spring Harbor, New York, USA: Cold Spring Harbor Laboratory Press; 1997.
8. McCune JM, et al. Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell. 1988;53(1):55-67.
9. Wlodawer A, Erickson JW. Structure-based inhibitors of HIV-1 protease. Annu Rev Biochem. 1993;62:543-585. (Pubitemid 23237881)
10. Gulnik S, Erickson JW, Xie D. HIV protease: Enzyme function and drug resistance. Vitam Horm. 2000;58:213-256.
11. Ali A, et al. Molecular basis for drug resistance in HIV-1 protease. Viruses. 2010;2(11):2509-2535.
12. Henderson GJ, et al. Interplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivity. Antimicrob Agents Chemother. 2012;56(2):623-633.
13. Kawamura M, et al. Cleavage of gag precursor is required for early replication phase of HIV-1. FEBS Lett. 1997;415(2):227-230. (Pubitemid 27430072)
14. Lori F, et al. Enzymatically active forms of reverse transcriptase of the human immunodeficiency virus. AIDS Res Hum Retroviruses. 1988;4(5):393-398.
15. Muller B, et al. HIV-1 gag processing intermediates trans-dominantly interfere with HIV-1 infectivity. J Biol Chem. 2009;284(43):29692-29703.
16. Davis MR, Jiang J, Zhou J, Freed EO, Aiken C. A mutation in the human immunodeficiency virus type 1 gag protein destabilizes the interaction of the envelope protein subunits gp120 and gp41. J Virol. 2006;80(5):2405-2417. (Pubitemid 43271546)
17. Murakami T, Ablan S, Freed EO, Tanaka Y. Regulation of human immunodeficiency virus type 1 env-mediated membrane fusion by viral protease activity. J Virol. 2004;78(2):1026-1031. (Pubitemid 38067625)
18. Wyma DJ, et al. Coupling of human immunodeficiency virus type 1 fusion to virion maturation: A novel role of the gp41 cytoplasmic tail. J Virol. 2004;78(7):3429-3435. (Pubitemid 38568284)
19. .Johnson VA, et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2011;19(4):156-164.
20. .Gallego O, et al. Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. AIDS . 2001;15(13):1701-1706. (Pubitemid 32918125)
21. Havlir DV, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA . 2000;283(2):229-234. (Pubitemid 30039223)
22. Pulido F, Arribas J, Hill A, Moecklinghoff C. No evidence for evolution of protease inhibitor resistance from standard genotyping, after 3 years of treatment with darunavir/ritonavir, with or without nucleoside analogues. AIDS Res Hum Retroviruses. 2012;28(10):1167-1169.
23. Taiwo B, et al. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS. 2011;25(17):2113-2122.
24. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.
25. Weiss JN. The hill equation revisited: Uses and misuses. FASEB J. 1997;11(11):835-841. (Pubitemid 27371892)
26. Hill A. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J Physiol. 1910;40(7):iv-vii.
27. Bliss CI. The toxicity of poisons jointly applied. Ann Appl Biol. 1939;26:585-615.
28. Balasubramaniam M, Freed EO. New insights into HIV assembly and trafficking. Physiology (Bethesda). 2011;26(4):236-251.
29. Hong SS, Boulanger P. Assembly-defective point mutants of the human immunodeficiency virus type 1 gag precursor phenotypically expressed in recombinant baculovirus-infected cells. J Virol . 1993;67(5):2787-2798. (Pubitemid 23118878)
30. Gottlinger HG, Sodroski JG, Haseltine WA. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A. 1989;86(15):5781-5785. (Pubitemid 19217537)
31. Smith AJ, Cho MI, Hammarskjold ML, Rekosh D. Human immunodeficiency virus type 1 Pr55gag and Pr160gag-pol expressed from a simian virus 40 late replacement vector are efficiently processed and assembled into viruslike particles. J Virol. 1990;64(6):2743-2750. (Pubitemid 20171262)
32. Pajonk F, Himmelsbach J, Riess K, Sommer A, McBride WH. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radio-sensitization in non-HIV-associated human cancer cells. Cancer Res. 2002;62(18):5230-5235. (Pubitemid 35024595)
33. Gupta AK, Li B, Cerniglia GJ, Ahmed MS, Hahn SM, Maity A. The HIV protease inhibitor nelfinavir downregulates akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response. Neoplasia. 2007;9(4):271-278. (Pubitemid 46608294)
34. Piccinini M, et al. The human 26S proteasome is a target of antiretroviral agents. AIDS. 2002;16(5):693-700. (Pubitemid 34274459)
35. Ott DE, Coren LV, Sowder RC 2nd, Adams J, Schubert U. Retroviruses have differing requirements for proteasome function in the budding process. J Virol. 2003;77(6):3384-3393. (Pubitemid 36297257)
36. Schubert U, et al. Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2. Proc Natl Acad Sci U S A. 2000;97(24):13057-13062.
37. Cavrois M, De Noronha C, Greene WC. A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat Biotechnol. 2002;20(11):1151-1154. (Pubitemid 35285446)
38. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS. HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure. Cell. 1990;61(2):213-222.
39. Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell. 2002;110(4):521-529. (Pubitemid 35232295)
40. Shan L, et al. Influence of host gene transcription level and orientation on HIV-1 latency in a primary-cell model. J Virol. 2011;85(11):5384-5393.
41. Butler SL, Hansen MS, Bushman FD. A quantitative assay for HIV DNA integration in vivo. Nat Med. 2001;7(5):631-634. (Pubitemid 32448333)
42. O'Doherty U, Swiggard WJ, Jeyakumar D, McGain D, Malim MH. A sensitive, quantitative assay for human immunodeficiency virus type 1 integration. J Virol. 2002;76(21):10942-10950. (Pubitemid 35176211)
43. Brussel A, Delelis O, Sonigo P. Alu-LTR real-time nested PCR assay for quantifying integrated HIV-1 DNA. Methods Mol Biol. 2005;304:139-154.
44. Zhang H, et al. Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J Virol . 2004;78(4):1718-1729. (Pubitemid 38176704)
45. Petropoulos CJ, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000;44(4):920-928. (Pubitemid 30165271)
46. Kiernan RE, Freed EO. Cleavage of the murine leukemia virus transmembrane env protein by human immunodeficiency virus type 1 protease: Transdominant inhibition by matrix mutations. J Virol. 1998;72(12):9621-9627. (Pubitemid 28520825)
47. Koh Y, et al. In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors. J Virol. 2010;84(22):11961-11969.
48. Sampah ME, Shen L, Jilek BL, Siliciano RF. Doseresponse curve slope is a missing dimension in the analysis of HIV-1 drug resistance. Proc Natl Acad Sci U S A. 2011;108(18):7613-7618.
49. Shen L, Siliciano RF. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol. 2008;122(1):22-28. (Pubitemid 351899083)
50. Kempf DJ, et al. Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother. 1991;35(11):2209-2214.
51. McQuade TJ, et al. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science. 1990;247(4941):454-456.
52. Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS. 2009;23(3):279-291.
53. Ashorn P, McQuade TJ, Thaisrivongs S, Tomasselli AG, Tarpley WG, Moss B. An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Proc Natl Acad Sci U S A. 1990;87(19):7472-7476. (Pubitemid 20341738)
54. Erickson J, et al. Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science. 1990;249(4968):527- 533.
55. Schatzl H, Gelderblom HR, Nitschko H, von der Helm K. Analysis of non-infectious HIV particles produced in presence of HIV proteinase inhibitor. Arch Virol. 1991;120(1-2):71-81.
56. Kaplan AH, et al. Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of non-infectious particles. J Virol. 1993;67(7):4050-4055. (Pubitemid 23180729)
57. Rosenbloom DI, Hill AL, Rabi SA, Siliciano RF, Nowak MA. Antiretroviral dynamics determines HIV evolution predicts therapy outcome. Nat Med. 2012;18(9):1378-1385.
58. Kempf DJ, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis. 2004;189(1):51-60. (Pubitemid 38122329)
59. Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L, Lamarre D. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol. 1996;70(6):3763-3769. (Pubitemid 26161824)
60. Dam E, et al. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Pathog. 2009;5(3):e1000345.
61. Gatanaga H, et al. Amino acid substitutions in gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors. J Biol Chem. 2002;277(8):5952- 5961. (Pubitemid 34968376)
62. Gupta RK, Kohli A, McCormick AL, Towers GJ, Pillay D, Parry CM. Full-length HIV-1 gag determines protease inhibitor susceptibility within in vitro assays. AIDS. 2010;24(11):1651-1655.
63. Kolli M, Stawiski E, Chappey C, Schiffer CA. Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance. J Virol. 2009;83(21):11027-11042.
64. Robinson LH, Myers RE, Snowden BW, Tisdale M, Blair ED. HIV type 1 protease cleavage site mutations and viral fitness: Implications for drug susceptibility phenotyping assays. AIDS Res Hum Retroviruses. 2000;16(12):1149-1156. (Pubitemid 30637016)
65. Parry CM, Kolli M, Myers RE, Cane PA, Schiffer C, Pillay D. Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity. Antimicrob Agents Chemother. 2011;55(3):1106-1113.
66. Chojnacki J, et al. Maturation-dependent HIV-1 surface protein redistribution revealed by fluorescence nanoscopy. Science. 2012;338(6106):524- 528.
67. Shan L, et al. A novel PCR assay for quantification of HIV-1 RNA. J Virol. 2013;87(11):6521-6525.
68. Pierson T, et al. Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1. J Virol. 2000;74(17):7824-7833. (Pubitemid 30641626)
69. Lengauer T, Sander O, Sierra S, Thielen A, Kaiser R. Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol. 2007;25(12):1407-1410. (Pubitemid 350233143)